Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Akorn, Inc.    AKRX

AKORN, INC.

(AKRX)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/11/2019 02/12/2019 02/13/2019 02/14/2019 02/15/2019 Date
4.06(c) 4.2(c) 4.27(c) 4.33(c) 4.44(c) Last
1 990 370 2 157 288 1 622 091 1 022 131 1 183 877 Volume
-1.93% +3.45% +1.67% +1.41% +2.54% Change
More quotes
Financials (USD)
Sales 2018 706 M
EBIT 2018 -164 M
Net income 2018 -223 M
Finance 2018 546 M
Yield 2018 -
Sales 2019 672 M
EBIT 2019 48,9 M
Net income 2019 -91,7 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 0,02x
Capi. / Sales2019 0,83x
Capitalization 557 M
More Financials
Company
Akorn Inc. (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The... 
Sector
Pharmaceuticals
Calendar
02/28Earnings Release
More about the company
Surperformance© ratings of Akorn, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on AKORN, INC.
02/11Akorn to Report Fourth Quarter and Full Year 2018 Results
GL
01/31INVESTIGATION REMINDER : The Schall Law Firm Announces it is Investigating Claim..
BU
01/30INVESTIGATION ALERT : The Schall Law Firm Announces it is Investigating Claims A..
BU
01/30Rosen Law Firm Announces Investigation of Securities Claims Against Akorn, In..
BU
01/28AKORN : Initial filing by director officer or owner of more than ten percent.
PU
01/28AKORN : Report of unscheduled material events or corporate event
PU
01/28AKORN INC : Change in Directors or Principal Officers, Regulation FD Disclosure,..
AQ
01/28Akorn Announces New Executive and Board Appointments
GL
01/24AKORN : An amendment to the SC 13G filing
PU
01/09Pomerantz Law Firm Investigates Claims On Behalf of Investors of Akorn, Inc. ..
PR
More news
Analyst Recommendations on AKORN, INC.
More recommendations
Sector news : Pharmaceuticals - NEC
02/17Cash-hoarding Japanese firms please investors as share buybacks hit record
RE
02/15BRISTOL MYERS SQUIBB : Starboard gauges Bristol-Myers shareholder support for Ce..
RE
02/15Bayer gains full Vitrakvi rights from Eli Lilly's Loxo
RE
02/15WSJ TAX GUIDE 2019 : What Investors Need to Know -2-
DJ
02/15WSJ TAX GUIDE 2019 : What Investors Need to Know -- Journal Report
DJ
More sector news : Pharmaceuticals - NEC
Chart AKORN, INC.
Duration : Period :
Akorn, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AKORN, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Average target price 8,00 $
Spread / Average Target 80%
EPS Revisions
Managers
NameTitle
Douglas S. Boothe President, Chief Executive Officer & Director
Alan D. Weinstein Chairman
Christopher C. Young Executive Vice President-Global Operations
Duane A. Portwood CFO & Executive Vice President
Mark M. Silverberg Executive VP-Operations & Technical Services
Sector and Competitors
1st jan.Capitalization (M$)
AKORN, INC.30.97%557
JOHNSON & JOHNSON5.68%365 768
PFIZER-2.86%245 920
ROCHE HOLDING LTD.11.98%233 242
NOVARTIS7.19%228 685
MERCK AND COMPANY4.45%207 536